7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.

      Antimicrobial Agents and Chemotherapy
      Amikacin, pharmacology, Aminoglycosides, Anti-Bacterial Agents, Cephalosporins, Clavulanic Acid, Gentamicins, Humans, Imipenem, Integrons, genetics, Molecular Sequence Data, Penicillanic Acid, analogs & derivatives, Piperacillin, Plasmids, Pseudomonas Infections, microbiology, Pseudomonas aeruginosa, drug effects, enzymology, isolation & purification, Spain, Thienamycins, beta-Lactamases

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Two clonally related Pseudomonas aeruginosa isolates, recovered from two patients admitted to a pediatric intensive care unit, were found to harbor a new OXA-2 variant (Asn148Asp), designated OXA-161. The plasmid location of bla(OXA-161) was demonstrated through electroporation to PAO1, and its codification in a class I integron (together with aacA4) was demonstrated through PCR and sequencing. bla(OXA-2) and bla(OXA-161) were cloned in parallel to demonstrate the extended-spectrum beta-lactamase properties of OXA-161, conferring resistance to ceftazidime and reduced susceptibility to cefepime and aztreonam.

          Related collections

          Author and article information

          Comments

          Comment on this article